Alwin Krämer
Alwin Krämer
Professor der Medizin, Universität Heidelberg
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
J Bartkova, Z Hořejší, K Koed, A Krämer, F Tort, K Zieger, P Guldberg, ...
Nature 434 (7035), 864-870, 2005
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease
S Stein, MG Ott, S Schultze-Strasser, A Jauch, B Burwinkel, A Kinner, ...
Nature medicine 16 (2), 198-204, 2010
Prediction of acute myeloid leukaemia risk in healthy individuals
S Abelson, G Collord, SWK Ng, O Weissbrod, N Mendelson Cohen, ...
Nature 559 (7714), 400-404, 2018
Centrosome-associated Chk1 prevents premature activation of cyclin-B–Cdk1 kinase
A Krämer, N Mailand, C Lukas, RG Syljuåsen, CJ Wilkinson, EA Nigg, ...
Nature cell biology 6 (9), 884-891, 2004
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2 …
C Röllig, H Serve, A Hüttmann, R Noppeney, C Müller-Tidow, U Krug, ...
The lancet oncology 16 (16), 1691-1699, 2015
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial
H Serve, U Krug, R Wagner, MC Sauerland, A Heinecke, U Brunnberg, ...
Journal of Clinical Oncology 31 (25), 3110-3118, 2013
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
JE Cortes, S Khaled, G Martinelli, AE Perl, S Ganguly, N Russell, ...
The lancet oncology 20 (7), 984-997, 2019
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
H Döhner, M Lübbert, W Fiedler, L Fouillard, A Haaland, JM Brandwein, ...
Blood, The Journal of the American Society of Hematology 124 (9), 1426-1433, 2014
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2 …
U Platzbecker, JM Middeke, K Sockel, R Herbst, D Wolf, CD Baldus, ...
The Lancet Oncology 19 (12), 1668-1679, 2018
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
J Cortes, AE Perl, H Döhner, H Kantarjian, G Martinelli, T Kovacsovics, ...
The Lancet Oncology 19 (7), 889-903, 2018
Aneuploidy correlated 100% with chemical transformation of Chinese hamster cells
R Li, G Yerganian, P Duesberg, A Kraemer, A Willer, C Rausch, ...
Proceedings of the National Academy of Sciences 94 (26), 14506-14511, 1997
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
T Placke, K Faber, A Nonami, SL Putwain, HR Salih, FH Heidel, A Krämer, ...
Blood, The Journal of the American Society of Hematology 124 (1), 13-23, 2014
Centrosome replication, genomic instability and cancer
A Krämer, K Neben, AD Ho
Leukemia 16 (5), 767-775, 2002
Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen
B Rebacz, TO Larsen, MH Clausen, MH Rønnest, H Löffler, AD Ho, ...
Cancer research 67 (13), 6342-6350, 2007
STIL is required for centriole duplication in human cells
J Vulprecht, A David, A Tibelius, A Castiel, G Konotop, F Liu, F Bestvater, ...
Journal of cell science 125 (5), 1353-1362, 2012
Proteins required for centrosome clustering in cancer cells
B Leber, B Maier, F Fuchs, J Chi, P Riffel, S Anderhub, L Wagner, AD Ho, ...
Science translational medicine 2 (33), 33ra38-33ra38, 2010
Aneuploidy precedes and segregates with chemical carcinogenesis
P Duesberg, R Li, D Rasnick, C Rausch, A Willer, A Kraemer, ...
Cancer Genetics and Cytogenetics 119 (2), 83-93, 2000
Structure meets function—centrosomes, genome maintenance and the DNA damage response
H Löffler, J Lukas, J Bartek, A Krämer
Experimental cell research 312 (14), 2633-2640, 2006
Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma
K Neben, T Moehler, A Benner, A Kraemer, G Egerer, AD Ho, ...
Clinical Cancer Research 8 (11), 3377-3382, 2002
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
A Chaturvedi, L Herbst, S Pusch, L Klett, R Goparaju, D Stichel, ...
Leukemia 31 (10), 2020-2028, 2017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20